✦ LIBER ✦

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

✍ Scribed by John G. McHutchison; Bruce R. Bacon; Stuart C. Gordon; Eric Lawitz; Mitchell Shiffman; Nezam H. Afdhal; Ira M. Jacobson; Andrew Muir; Mohammed Al-Adhami; Mary L. Morris; Julie A. Lekstrom-Himes; Susan M. Efler; Heather L. Davis

Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 397 KB
Volume: 46
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.21773

No coin nor oath required. For personal study only.

✦ Synopsis

CPG 10101, a synthetic oligodeoxynucleotide (ODN), is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV. In this multicenter Phase 1b trial, 60 HCV-positive patients (50 genotype 1 HCV) were randomized and received either placebo or CPG 10101 at 0.25, 1, 4, 10, or 20 mg subcutaneously (SC) twice weekly for 4 weeks or at 0.5 or 0.75 mg/kg SC once weekly for 4 weeks. Dose-dependent cytokine induction was observed after administration of CPG 10101. At 24 hours after administering the highest dose of 0.75 mg/kg CPG 10101, interferon (IFN)-␥inducible protein 10 (IP-10) had a mean increase over baseline levels (؎SD) of 15,057 (؎9769) pg/ml (P < 0.01, compared to placebo); IFN-␣ had a 106 (؎63.3) pg/ml increase (P < 0.01); and 25-oligoadenylate synthetase (OAS) had a 163 (؎120.6) pmol/dl increase (P < 0.01). Decreases in HCV RNA also were dose-dependent, with the greatest group geometric mean maximum reduction of 1.69 ؎ 0.618 log 10 (P < 0.05) observed in the 0.75 mg/kg dose group. Decreases >1 log 10 were seen in 22 of 40 patients who received >1 mg CPG 10101, with 3 patients exceeding a 2.5-log 10 reduction. CPG 10101 was well tolerated, and adverse events were consistent with CPG 10101's mechanism of action. Conclusion: In this Phase 1 study, CPG 10101 was associated with dose-dependent increases in markers of immune activation and decreases in HCV RNA levels. The data support further clinical studies of CPG 10101 for treating chronic HCV infection. (HEPATOLOGY 2007

📜 SIMILAR VOLUMES

A phase II dose-escalating trial of clev

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B

✍ Patrick Marcellin; Herve Mommeja-Marin; Stephen L. Sacks; George K. K. Lau; Dani 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB 👁 1 views

Current therapies available for the treatment of chronic hepatitis B are limited in their ability to result in a cure. Clevudine is a new pyrimidine analog with potent anti-hepatitis B virus (HBV) activity in vitro. A multicenter dose-escalation study evaluated clevudine at 10, 50, 100, and 200 mg o

Telbivudine versus lamivudine in Chinese

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial

✍ Jinlin Hou; You-Kuan Yin; Daozhen Xu; Deming Tan; Junqi Niu; Xiaqiu Zhou; Yuming 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB

Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudin

Response to higher doses of interferon a

Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: A randomized multicenter trial

✍ K L Lindsay; G L Davis; E R Schiff; H C Bodenheimer; L A Balart; J L Dienstag; R 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

JANICE ALBRECHT, 12 AND THE HEPATITIS INTERVENTIONAL THERAPY GROUP\* with continued therapy at that dose; however, a propor-To evaluate response rates to 3, 5, or 10 million units tion of patients who do not respond to 12 weeks of treat-(MU) of interferon alfa-2b, given thrice weekly, and to ment wi

A randomized controlled trial of thymosi

A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody—and hepatitis B virus DNA—positive chronic hepatitis B

✍ P Andreone; C Cursaro; A Gramenzi; C Zavaglia; I Rezakovic; E Altomare; R Severi 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

ment for anti-HBe-positive chronic hepatitis. The benefit It has recently been shown that thymosin-a 1 (T-a 1 ), a of this agent in producing long-term inhibition of HBV synthetic polypeptide of thymic origin, is able to proreplication must be confirmed by future trials. (HEPAmote disease remission

Reduced B lymphocyte and immunoglobulin

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial

✍ Maria Dall'Era; Eliza Chakravarty; Daniel Wallace; Mark Genovese; Michael Weisma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 2 views

Final results of a double-blind, placebo

Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-γ1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis

✍ Paul J. Pockros; Lennox Jeffers; Nezam Afdhal; Zachary D. Goodman; David Nelson; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 383 KB 👁 2 views

## Interferon-␥1b (IFN-␥1b ) is a pleiotropic cytokine that displays antifibrotic, antiviral, and antiproliferative activity. A total of 502 patients with compensated liver disease and an Ishak fibrosis score of 4-6 were randomized in a double-blind, placebo-controlled study, and 488 of these pati